Therapeutic vulnerabilities in the DNA damage response for the treatment of ATRX mutant neuroblastoma.

Compounds where the fixed effect ( ATRX gene status) was nominally significant (uncorrected p-value ≤ 0.05) were selected.

also in 7,732 other papers

Fourteen compounds met the criteria for selective resistance in the ATRX mutants, including three different histone deacetylase (HDAC) inhibitors and two different aurora kinase inhibitors, where a clear trend towards relative resistance was identified for multiple compounds from both classes of agent ( Fig. 3 a, Fig.

also in 19,460 other papers